Contemporary Use of Anticancer Drugs Requiring Dose Modification for GFR in US Adults with CKD (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1232; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The most common agents were pembrolizumab (10.1%), paclitaxel (9.7%), doxorubicin (9.4%), carboplatin (8.1%), gemcitabine (7.9%), rituximab (7.7%), cyclophosphamide (7.3%), and cisplatin (4.6%). Conclusion Anticancer drugs that require dose adjustment based on GFR are frequently used in patients with CKD. Our findings highlight a potential gap in precision dosing due to the lack of availability of mGFR and underscore the need for its wider availability to optimize cancer care for individuals with CKD and cancer."
Clinical • Chronic Kidney Disease • Nephrology • Oncology
|
|
Amin Tajerian; Linda Highfield; Gayla Ferguson; Carla Pezzia; Harry Liu; Tariq Shafi
|